Background/Aims: Pancreatic cancer cells (PCC) is one of the most risky cancers and gemcitabine (GEM) is the standard first-line drug for treating PCC. The PCC will develop drug resistance to GEM after a period of treatment. However, the detailed molecular mechanism of pathogenesis and drug resistance remains unresolved. Methods: we employed qRT-PCR and western blot to examine the expression level of CXCR4, let-7a and HMGA2. In addition, we used MTT assay to detect cell proliferation and transwell assay to measure migration and invasiveness. The expression level of epithelial marker E-cadherin and mesenthymal marker N-cadherin was detected by western blot. The apoptosis was determined using annexin V-FITC/PI apoptosis detection kit by flow cytometry. Results: we first proved that CXCR4 negatively regulated let-7a in PCC. Next, let-7a was confirmed to play crucial role in tumorigenesis, metastasis and drug resistance of pancreatic cancer cells Bxpc-3 and Panc-1 in vitro and in vivo. Finally, we identified HMGA2 as important downsteam target of let-7a in PCC and overexpression of HMGA2 restores cell proliferation, metastasis and chemosensitivity of GEM inhibited by let-7a. Conlusion: Taken together, we show an important signaling pathway involved in pathogenesis and drug resistance of PCC, thereby providing deeper insight into molecular mechanism by which CXCR4/let-7a regulates tumorigenesis and drug resistance of PCC. These findings will help us develop new strategies for diagnosis and treatment of PCC.
Introduction
Pancreatic cancer, derived from normal pancreatic ductal epithelial cells, is one of the most risky cancer types [1] [2] [3] [4] . Although the pathogenesis of pancreatic cancer cells has been well-studied for a long time, the exact molecular mechanism underlying drug resistance remains unclear. It has been well-established that cancers, including pancreatic cancer cells, are caused by accumulated genetic lesions [5] . Inactivation of TP53, SMAD4 and TGFβ have been found by large-scale genome sequencing of pancreatic cancer cells samples [6, 7] .
Despite increasing knowledge of understanding the reason for pathogenesis of pancreatic cancer cells, the effective anti-pancreatic cancer drug remains scarce. Currently, GEM is still thought as the standard drug to treat pancreatic cancer [3, 8] , however, not all cases respond similarly to GEM due to primary and acquired drug resistance. Therefore, it is an important field of fully understanding the mechanism underlying the drug resistance.
CXCR4, the chemokine receptor, has been reported to play an critical role in tumorigenesis and metastasis of non small cell lung cancer (NSCLC) and pancreatic cancer [9, 10] . More importantly, the recent studies revealed that CXCR4 is correlated with different degree of chemosensitivity of a variety of cancer types, including chemosensitivity of panceatic cancer to GEM [11] [12] [13] [14] [15] . Some researches has implicated some miRNAs (like miR-21, miR-200, miR-145) and p85 in the regulation of drug resistance of pancreatic cancer to GEM [1, 8, [16] [17] [18] . In 2010, Miao Zhong et al. demonstrated that overexpression of let-7a, hsa-miR-126 and hsa-miR-145 enhanced the sensitivity of non-small cell lung cancer (NSCLC) cells to gefitinib [19] . Consequently, overexpression of tumor-suppressive microRNAs might be a promising therapeutical strategies for cancers, including pancreatic cancer. Let-7a has been recognized as downstream target gene of CXCR4 responsible for chemosensitivity [12] . Nonetheless, the detailed mechanistics of how CXCR4 influences chemosensitivity of panceatic cancer to GEM is not fully understood, which becomes an urgent issue to be addressed.
Let-7a, a member of microRNA let-7 family, has been linked to various cancer types, e.g., breast cancer, non small cell lung cancer (NSCLC), pancreatic cancer, colon cancer [19] [20] [21] [22] . It has been reported that overexpression of let-7a could sensitize resistant breast cancer cells to epirubicin in vitro [22] . In some studies, let-7a has been shown to inversely correlate with well-known oncogenes, including HMGA2 [23] , and positively regulate classical apoptosisrelated gene CASP3 [24] . These findings revealed that let-7a is likely to modulate many downstream target genes reponsible for drug resistance of pancreatic cancer.
Here, we investigate the role of signaling pathway CXCR4/let-7a/HMGA2 in the pathogenesis of pancreatic cancer and chemosensitivity to GEM. In this study, we found that CXCR4 negatively correlates with let-7a and regulates the expression level of let-7a in pancreatic cancer cell lines Panc-1 and BxPc3. Next, let-7a was proven to inhibit cell proliferation, metastasis and chemosensitivity of pancreatic cancer cells in vitro and in vivo. Finally, we identified HMGA2 as crucial downstream target for let-7a-induced phenotypes. To summarize, we highlight the indispensible role of CXCR4/let-7a/HMGA2 pathway in tumor-associated phenotypes and chemosensitivity of pancreatic cancer cells to GEM, which provides deeper understanding of pathogenesis and drug resistance of pancreatic cancer cell and helps develop more robust therapies for treating pancreatic cancer.
Materials and Methods

Cell culture
Human pancreatic ductal epithelial cells (HPDE6-C7) were cultured in keratinocyte serum-free (KSF) medium with 0.2 ng/ml EGF and 30 µg/ml bovine pituitary extract (Gibco). Pancreatic cancer cell lines Panc-1 and BxPc3 were grown in Dulbecco's Modified Eagle's Medium (DMEM) (hyclone) supplemented with 10% fetal bovine serum (FBS) (BI) and 1% penicillin (100 U/ml)/streptomycin (100 U/ml) (Invitrogen) at 37 °C under 5% CO2. 
Tissue samples
Western blot
Western blot analysis were performed as previously described [15] . Briefly, the cell pellet was resolved in 2×SDS loading buffer to make sample, 50ug of protein were loaded onto SDS-PAGE gel and subject to transfer to PVDF membrane, next, the membrane was blocked with 5% milk for 1h. primary and secondary antibodies were used to probe the target proteins, finally, the membrane were incubated with ECL and detected by bio-rad machine. The following antibodies were used: HMGA2 (Cell Signaling), rabbit polyclonal CXCR4 (Abcam), E-cadherin (BD Transduction), N-cadherin (BD Transduction) and β-actin (Sigma)
Real-time quantitative polymerase chain reaction (qRT-PCR)
Total RNA were extracted using Trizol as described earlier [14] . Then, 1ug RNA was subject to reverse transcription using the TAKARA PrimeScript Kit. For real time PCR, we performed this experiment using SYBR(Roche) as dye and detected the signal according to the standard protocol. The following primers were used:
CXCR4-F: AGCTGTTGGCTGAAAAGGTGGTCTATG, CXCR4-R: GCGCTTCTGGTGGCCCTTGGAGTGTG; let-7a-F: GATTCCTTTTCACCATTCACCCTGGATGTT, let-7a-R: TTTCTATCAGACCGCCTGGATGCAGACTTT; HMGA2-F: CTCAAAAGAAAGCAGAAGCCACTG, HMGA2-R: TGAGCAGGCTTCTTCTGAACAACT; U6 was used to normalize and the sequences: U6-F: GGTGAGGTAGTAGGTTGTATAGTT, U6-R: CTCGCTTCGGCAGCACATATA.
Luciferase reporter assays
The HMGA2 wild-type and mutant 3'-UTR were created and cloned to the firefly luciferase-expressing vector psiCHECK-2. For the luciferase assay, cells were seeded triplicate in 12-well plates the day before transfection, and transfected with the HMGA2 WT or Mut 3'-UTR reporter vector, the cells were harvested and lysed, and the luciferase activities were assayed using the Dual-Luciferase Reporter System (Promega). Three independent experiments were performed.
Transwell assay
The cells were transfected with let-7a mimic or HMGA2. 24 hours later, the cells were starved in medium without serum for another 12 hr and then digested with trypsin, and then seeded on the top chambers of 24 well transwell culture inserts (promega). The medium supplemented with 20% serum was used as chemoattractant. After 24 hr, The cells were fixed for 10 min with 4% formalin.
Invasion assays were performed using the BD Bio-Coat Matrigel invasion assay system (BD Biosciences) according to the manufacturer's instructions [14] . The nontile or noninvasive cells were removed, while the lower side of the filter were stained with 0.005% crystal violet and counted.
Cell viability assay
This experiment was performed as described [15] . In brief, the cells were seeded in 96-well plates at a density of 5000 cells per well, after the treatment, cell growth was examined using MTT cell proliferation assay. The absorbance of cells were determined at OD490nm.
Flow cytometry
Cells (2×10 5 cells) were digested by trypsin and then washed with PBS, next, the cells were subject to be washed with annexin V-binding buffer followed by incubation with 5 μl annexin V-FITC and 5 μl propidium iodide for 15 min at room temperature in the dark. Cells were then washed with binding buffer and subject to FACS. Bxpc-3 and Panc-1 were both grouped into wildtype, negative control and let-7a overexpression, and then treated with GEM at the concentration of 0.5μM and 100μM, respectively. Xenograft experiment A total of 48 nude mice between the ages of 5-6 week old were used per treatment for tumour xenograft experiments. Panc-1 cells were tansfected with control or let-7a vector, 48h later, 1×10 6 cells were collected and injected subcutaneously per mouse. After 15 days, these mice were subject to PBS or 100mg/kg GEM injection every week untill harvest. Tumour size and weight were measured. All mice were euthanized 35 days after subcutaneous injection. Tumours were then excised and photographed.
Statistical analysis
Each experiment was performed for three times, and all values were expressed as mean ± S.D., The differences between the groups were compared using two-tailed student's t -tests. *p < 0.05; **p < 0.01.
Results
CXCR4 downregulates let-7a level in PCC
Based on the published studies, we hypothized that CXCR4 regualtes the let-7a expression level in pancreatic tumor cells. So, we first examined the let-7a gene expression level in a variety of clinical normal and pancreatic tumor tissues. In agreement with previous studies, the result showed that let-7a was decreased in tumor tissues compared to normal pancreatic tissue (Fig. 1A) . In addition, we observed that let-7a inversely correlated with CXCR4 
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expression by spearman analysis in pancreatic tumor tissues (Fig. 1B) . To be a validation, we examined the CXCR4 mRNA and protein levels in various normal and pancreatic tumor cell lines ( Fig. 1C and 1D ). These data revealed that CXCR4 highly expressed in pancreatic tumor cells and lowly in normal pancreatic cell line (HPDE6-C7). Instead, the normal pancreatic cell line (HPDE6-C7) expressed more abundant let-7a (Fig. 1E ). What , s more, we detected let-7a level in two pancreatic tumor cells Bxpc-3 and Panc-1 treated with 100ng/ml SDF-1a, cognate ligand of CXCR4 [13, 25] . The let-7a level decreased by ~50%, indicating the ability of CXCR4 to regulate let-7a level in pancreatic tumor cells (Fig. 1F) . On the other hand, the let-7a mRNA level increased markedly after the cells treated with potent CXCR4 inhibitor, AMD3100 (200nM) (Fig. 1G) . Taken together, we suggest that CXCR4 is likely to function in pathogenesis of PCC via let-7a.
Let-7a suppresses cell proliferation and metastasis of PCC
Although it has been reported that let-7a play important role in cancer cell proliferation, invasiveness, metastasis, we determined whether let-7a functions similarly in our study 
Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry
marker N-cadherin substantially declined after overexpressing let-7a mimic in Bxpc-3 and Panc-1 cell (Fig. 2E) . Altogether, these data suggested that let-7a played critical role in pancreatic tumor cells proliferation, invasiveness and metastasis.
Let-7a increases chemosensitivity of PCC to GEM in vitro
It has been reported that let-7a has the capacity to sensitize cancer cells to chemotherapy drugs, but the effect of let-7a on drug resistance of PCC has not been studied. Hence, we attempted to determine whether let-7a enhance chemosensitivity of pancreatic tumor cell Bxpc-3 and Panc-1 to GEM. The result showed that let-7a overexpression decreased the IC 50 value of Bxpc-3 from about 1.25μM to 1μM and that of Panc-1 from about 250μM to 200μM (Fig. 3A) . The cell viability assay showed that let-7a overexpression led to growth retardation of these two cell lines in the presence of GEM (Fig. 3B) . Besides, we performed apoptosis assay by flow cytometry, we observed that let-7a markedly increased the apoptosis rate induced by GEM from about 2.9% to 22.4%, 3.3% to 6.8% Bxpc-1 and Panc-1 cells, respectively, compared to wildtype control (Control) (Fig. 3C and 3D ). Taken together, let-7a increases chemosensitivity of pancreatic cancer cells Bxpc-3 and Panc-1 to GEM.
Let-7a inhibits tumorigenesis and increases chemosensitivity of PCC to GEM in vivo
To further confirm that let-7a is responsible for increased sensitivity of pancreatic cancer cell to GEM, we undertook exnograft experiment of implanting let-7a-overexpressed cell into immunodeficient nude mice. We chose Bxpc-3 cell for the in vivo models. When the mice intracranially transplanted with Lv-let-7a that stably express let-7a, or control lentiviral empty vector (vector) (Fig. 4A) . The result demonstrated that cells-overexpressing let-7a not only leaded to a significant inhibitory effect on tumorigenesis but also exerted more sensitivity to GEM (Fig. 4B and 4C) . To verify the expression of let-7a in xenograft tumors, we extracted and determined the let-7a mRNA level of these tumors by qRT-PCR. As shown in Fig. 4D , there was a higher expression in LV-let-7a group. Taken together, let-7a played a crucial role in tumorigenesis and sensitivity of pancreatic cancer cell to GEM in vivo.
HMGA2 acts as downstream target of let-7a in PCC
To interrogate the molecular mechanism by which let-7a inhibits cell proliferation, invasiveness and chemoresistance of PCC, we needed to find out the downstream target of 
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Cellular Physiology and Biochemistry let-7a. According to bioinformatic analysis (http://www.microrna.org) and previous studies, we focused on HMGA2, a directly targeted gene by let-7a [26, 27] (Fig. 5A ). To verify this finding, we conducted luciferase reporter assay. We observed that co-transfection of let-7a mimics and psi-HMGA2-wt significantly decreased the luciferase activity in Bxpc-3 and Panc-1 cells as compared with the negative control (NC). Moreover, let-7a mimics had no effect on 
Cellular Physiology and Biochemistry the luciferase activity when co-transfected with psi-HMGA2-mut (Fig. 5B ). In addition, we detected HMGA2 mRNA and protein level upon let-7a overexpression. The result showed that let-7a reduced HMGA2 protein level, while mRNA remained unchanged ( Fig. 5C and  5D ). Therefore, our results suggest that let-7a possibly decreased protein level of HMGA2 via binding 3'-UTR to impede translation of its mRNA.
Overexpression of HMGA2 reverses the inhibitory effect of let-7a on cell growth and metastasis
As HMGA2 was negatively regulated by let-7a, and a let-7a mimic can inhibitor cell growth and metastasis, we hypothesized that the overexpression of HMGA2 could lead to the same result. We examined the cell proliferation of Bxpc-3 and Panc-1 transfected with let-7a mimic alone or in combination with HMGA2 (Fig. 6A) . Surprisingly, HMGA2 overepression substantially rescued let-7a-induced cell proliferation retardation (Fig. 6B) . Then, we used the transwell assay to detect the invasiveness capacity of PCC cells. Similarly, overexpressed HMGA2 was able to partially reconstitute the invasiveness capacity of Bxpc-3 and Panc-1 cell (Fig. 6C) .
Overexpression of HMGA2 impairs the role of let-7a on increasing the sensitivity of PCC cells to gemcitabine
To verify that let-7a enhances sensitivity of PCC cells to GEM through negatively regulating HMGA2 expression, we first used the MTT assay to detect the cell proliferation of PCC cell in different GEM concentrations. The result shown that the regulatory ability of let-7a on 
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Cellular Physiology and Biochemistry the sensitivity of PCC cell lines to GEM was reversed when HMGA2 was overexpressed (Fig.  7A) . Additionally, overexpression of HMGA2 blocked apoptosis resulted from let-7a mimic overexpression (Fig. 7B, C) . Finally, we investigated whether HMGA2 could antagonized the increased sensitivity of cells to GEM caused by let-7a. We knocked down HMGA2 using short interference RNA, resulting in decreased IC 50 value (Fig. 7D) .To sum up, HMGA2 acted as downsteam effector of let-7a to markedly antagonize alteration of cell chemosensitivity of pancreatic cancer cells caused by let-7a.
Discussion
Pancreatic cancer remains one of the most lethal malignancies, and insights into both personalized diagnosis and intervention of this disease are urgently needed. For patients with advanced pancreatic cancer, it is common to treat the patients with chemical drugs; however, the resulting drug resistance leads to decreased efficacy. In this study, we identifed CXCR4/ let-7a/HMGA2 pathway to regulate cell proliferation, metastasis and drug resistance of PCC. We first proved that CXCR4 inversely correlates with let-7a in PCC and CXCR4 negatively regulates let-7a level at tissue and cellular level. This finding prompted us to concentrate our attention on let-7a, a well-studied miRNA implicated in cancer cell tumorigenesis, metastasis and chemosensitivity. We next investigated the role of let-7a in PCC and confirmed let7a functions similarly like in other types of cancer cells. Finally, we identified HMGA2 as downsteam target of let-7a to modulate cell proliferation, metastasis and chemosensitivity to GEM. In sum, we report a whole pathway responsible for tumorigenesis, metastasis and chemosensitivity to GEM in pancreatic cancer cells.
CXCR4 is a chemokine receptor and activated by its ligand SDF-1a [25] . And CXCR4 has been reported to play oncogenic role in various types of cancers (including pancreatic cancer) and enhance drug resistance of PCC [9, 13, 14] . Meanwhile, it had report that CXCR4 was inversely correlate with let-7a in acute myeloid leukemia [12] . It has been recognized that let-7a play suppressive role in tumorigenesis and chemosensitivity of cancer cells [19, 20, 28] . However, the role of CXCR4/let-7a in tumorigenesis and drug resistance of PCC remains not well-studied. Thus, we interrogated the role of CXCR4/let-7a in proliferation, metastasis and drug resistance of pancreatic cancer cells in vitro and in vivo. Consistently, the results demonstrates that let-7a inhibits tumorigenesis and drug resistance of PCC.
Although let-7a has been well-established to play important role in cell proliferation, invasiveness, metastasis and drug resistance, the molecular mechanism by which let7a functions is not fully known. Recently, let-7a seems to exert its function through regulation of HMGA2 expression in nasopharyngeal carcinoma and esophageal squamous cell carcinoma [29, 30] . By combination of bioinformatic prediction and experimental confirmation, we identified HMGA2 as downstream target of let-7a in PCC and effector in let-7a-induced attenuated cell proliferation, metastasis and drug resistance of PCC. However, to systematically identify downstream target of let-7a, we can utilize RNA-seq approach to search for all directly and indirectly regulated genes by let-7a reponsible for tumorigenesis, metastasis and drug resistance of PCC.
In summary, we propose a signaling pathway CXCR4/let-7a/HMGA2 responsible for regulation of cell proliferation, metastasis and drug resistance of PCC. These findings will help provide a solid foundation for understanding the molecular basis of pathogenesis and drug resistance of pancreatic cancer cells and develop new strategies for prevention, diagnosis and treatment of PCC.
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